

For seizures associated with **Lennox-Gastaut syndrome (LGS)** in patients ages 2 and older

Fintepla[®]
(fenfluramine)
2.2 mg/mL oral solution

**DISCOVER THE
POSSIBILITIES OF PROGRESS**

Ezekiel, living
life with LGS

**WORTH
FIGHTING
FOR**

Get the facts about FINTEPLA, including information about seizure reduction, resources, and support.

INDICATION

- FINTEPLA is a prescription medicine used to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older.
- It is not known if FINTEPLA is safe and effective in children less than 2 years of age.

SELECT IMPORTANT SAFETY INFORMATION

FINTEPLA can cause serious side effects, including:

Problems with the valves in the heart (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension) have been associated with FINTEPLA.

Your healthcare provider will do a test called an echocardiogram to check your heart and to evaluate for high blood pressure in the arteries of the lungs before you start taking FINTEPLA, again every 6 months during treatment, and one time 3 to 6 months after you take your last dose of FINTEPLA.

Please see full Important Safety Information on pages 13-15 and full Prescribing Information, including Medication Guide.



ALLISON, LIVING WITH LGS

FIND RESOURCES ABOUT LGS AT [SHINEFORWARDWITHLGS.COM](https://www.shineforwardwithlgs.com)

Understanding LGS and the risks of uncontrolled seizures

LGS is a form of epilepsy associated with multiple types of seizures that start in childhood. It is characterized by frequent, uncontrolled seizures that are difficult to treat and may take a toll on everyone involved.

Some of the challenges facing families who have a loved one with LGS include:



Dangerous, life-threatening seizure activity despite multiple ASMs



Devastating consequences on a patient's growth and development

22x

Higher risk of SUDEP in patients having life-threatening seizures* (seizures resulting in drops or falls: GTC, tonic, atonic, and tonic-atonic) than in other forms of epilepsy



Unwanted side effects from taking multiple ASMs

ASMs, antiseizure medications; GTC, generalized tonic-clonic; SUDEP, sudden unexpected death in epilepsy.

*The most common causes of death were related to neurologic events, primarily epilepsy.

What makes FINTEPLA different from other ASMs?

Here are some of the reasons to consider talking with your loved one's healthcare team about FINTEPLA:



Reductions across multiple seizure types

Significant reductions across multiple seizure types associated with LGS, including life-threatening seizures (seizures resulting in drops or falls: GTC, tonic, atonic, and tonic-atonic). (pg 5)



Well-established safety profile

Approved by the US FDA for seizures associated with Dravet syndrome and LGS. FINTEPLA was approved based on the safety and efficacy results from clinical trials. (pg 6)



Fits into your loved one's treatment plan

No adjustments to baseline ASMs are needed as FINTEPLA works differently from other ASMs. FINTEPLA has not shown a meaningful impact on how the body interacts with other ASMs. (pg 10)

Since the approval of FINTEPLA in June 2020 for seizures associated with Dravet syndrome and March 2022 for seizures associated with LGS, more than 10,000 patients worldwide have been prescribed FINTEPLA.

Watch a video about how FINTEPLA can fit into your loved one's current treatment plan at [FINTEPLA.com](https://www.fintepla.com).

IMPORTANT SAFETY INFORMATION

FINTEPLA can cause serious side effects, including:

- 1. Problems with the valves in the heart (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension)** have been associated with FINTEPLA. Your healthcare provider will do a test called an echocardiogram to check your heart and to evaluate for high blood pressure in the arteries of the lungs before you start taking FINTEPLA, again every 6 months during treatment, and one time 3 to 6 months after you take your last dose of FINTEPLA.

Significant and maintained seizure reduction across seizure types commonly experienced in LGS

In a 14-week clinical study:

FINTEPLA REDUCED


MONTHLY DROP SEIZURES BY **24%** COMPARED WITH 9% FOR PATIENTS TAKING PLACEBO

Seizures that were confirmed to result in drops.

Drop seizures included generalized tonic-clonic (GTC), tonic, atonic, and tonic-atonic.

Patients added either FINTEPLA (0.7 mg/kg/day) or placebo to their current antiseizure treatment plans. In the clinical study, 0.7 mg/kg/day was the only dose of FINTEPLA to **significantly reduce monthly drop seizures**. Results may vary.

Seizure reduction was maintained throughout the 14-week study period.



IMPORTANT SAFETY INFORMATION (cont.)

Call your healthcare provider right away if you develop any of these signs and symptoms of heart or lung problems during treatment with FINTEPLA:

- shortness of breath
- chest pain
- tiredness or weakness, especially with increased activity
- sensations of a rapid, fluttering heartbeat (palpitations)
- lightheadedness or fainting
- irregular pulse
- swollen ankles or feet
- bluish color of your lips and skin (cyanosis)

Please see full Important Safety Information on pages 13-15 and full Prescribing Information, including Medication Guide.

FINTEPLA was studied in patients experiencing serious and hard-to-treat seizures

263 patients with LGS enrolled in the clinical study. It compared reduction in seizures resulting in a drop between 2 different doses of FINTEPLA (0.7 mg/kg/day and 0.2 mg/kg/day) and placebo over a **14-week treatment period**.

All patients in the clinical study were between ages **2 and 35 years** (with 29% over age 18 years).

Before the Study



Patients had been treated with an average of **7 other antiseizure medicines**.



Patients were having at **least 8—and an average of 194**—seizures that resulted in drops, falls, or injuries per month.



Some patients had **interventional procedures**, such as vagal nerve stimulation or a corpus callosotomy.

During the Study



All patients were being treated with **1 to 4 other antiseizure medicines or treatments**.

The most common medicines were clobazam, lamotrigine, and valproate. Treatment plans included the ketogenic diet.

Patients were randomly placed into 1 of 3 groups where they took 0.7 mg/kg/day of FINTEPLA, 0.2 mg/kg/day of FINTEPLA, or placebo. All patients added FINTEPLA or placebo to their current antiseizure treatment plans.


In the clinical study, 0.7 mg/kg/day was the only dose of FINTEPLA to significantly reduce monthly drop seizures.

IMPORTANT SAFETY INFORMATION (cont.)

Because of the risk of heart valve problems (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension), FINTEPLA is only available through a restricted program called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS). Before you or your child receives FINTEPLA, your healthcare provider or pharmacist will make sure you understand how to take FINTEPLA safely. If you have any questions about FINTEPLA, ask your healthcare provider, visit www.FinteplaREMS.com, or call 1-877-964-3649.

Clinical Global Impression–Improvement (CGI-I)

At the end of the 14-week study of FINTEPLA for LGS, each patient’s healthcare provider and parent or caregiver compared the patient’s overall functioning to how it was before starting treatment with FINTEPLA. Both groups ranked overall functioning using CGI-I, a 7-point scale where 1 is “Very Much Improved” and 7 is “Very Much Worse.”



More healthcare providers and caregivers saw an improvement* on the CGI-I scale for patients treated with FINTEPLA than patients treated with placebo.

*A score of 1 to 3 means improvement; a score of 4 means no change; a score of 5 to 7 means worsening.

IMPORTANT SAFETY INFORMATION (cont.)

- 2. Decreased appetite and decreased weight.** Decreased appetite and decreased weight are serious and common side effects of FINTEPLA.
- Your weight should be checked regularly during your treatment with FINTEPLA.
 - Your healthcare provider may need to make changes to your FINTEPLA dose if your weight decreases. In some cases, FINTEPLA may need to be stopped.

Please see full Important Safety Information on pages 13-15 and full Prescribing Information, including Medication Guide.

WORTH FIGHTING FOR

Hayden,
living with LGS

Throughout the **15-month, long-term, open-label extension study of FINTEPLA, most patients maintained the seizure reduction they experienced in the clinical study.**

Since this was an open-label, flexible-dose study, no conclusions of efficacy or safety should be made based on these results. Results may vary.

IMPORTANT SAFETY INFORMATION (cont.)

- 3. Sleepiness, sedation, and lack of energy (lethargy).** These are serious and common side effects of FINTEPLA. Taking FINTEPLA with central nervous system (CNS) depressants, including alcohol, may increase sleepiness. **Do not** drive, operate heavy machinery, or do other dangerous activities until you know how FINTEPLA affects you.

Long-term studies results

After the original clinical study:

94% **OF PATIENTS**
CONTINUED WITH FINTEPLA
AND PARTICIPATED IN A LONG-TERM,
OPEN-LABEL EXTENSION STUDY

*An open-label study means patients knew they were being treated with FINTEPLA and not a placebo.

In this open-label extension study:

50% of patients EXPERIENCED **≥7** drop seizure-free days in a row

25% of patients EXPERIENCED **≥17** drop seizure-free days in a row

Patients added FINTEPLA (up to 0.7 mg/kg/day) to their current antiseizure treatment plans. Since this was an open-label, flexible-dose study, no conclusions of efficacy or safety should be made based on these results. Results may vary.

IMPORTANT SAFETY INFORMATION (cont.)

- 4. Like all other antiepileptic drugs, FINTEPLA may cause suicidal thoughts or actions** in a very small number of people (about 1 in 500). **Call your healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:** thoughts about suicide or dying; trouble sleeping (insomnia); attempts to commit suicide; new or worse irritability; new or worse depression; acting aggressive, being angry or violent; new or worse anxiety; acting on dangerous impulses; feeling agitated or restless; an extreme increase in activity and talking (mania); panic attacks; other unusual changes in behavior or mood.

Please see full Important Safety Information on pages 13-15 and full [Prescribing Information](#), including [Medication Guide](#).

FINTEPLA can fit into current treatment plans

In most cases, FINTEPLA can be **added without disrupting current treatments or compromising progress** made with them.*†



FINTEPLA is a twice-daily oral solution that is cherry flavored and **can be taken with or without food.**



FINTEPLA is **compatible with gastric and nasogastric feeding tubes.**



There are no dietary restrictions while taking FINTEPLA—including being on the ketogenic diet.



No adjustments to baseline ASMs necessary; add FINTEPLA without disruptions to current ASMs.

Watch a video about how FINTEPLA can fit into your loved one's current treatment plan at [FINTEPLA.com](https://www.fintepla.com).

Though your loved one's current antiseizure treatment plan does not need to be adjusted when adding FINTEPLA, the maximum daily dose of FINTEPLA may need to be adjusted if your loved one is also taking certain other therapeutic medicines or has certain other medical conditions.

Patients with LGS adding FINTEPLA should start at the 0.2 mg/kg/day dose and increase weekly based on tolerability to a maximum recommended maintenance dose of 0.7 mg/kg/day.

*Your loved one should not take FINTEPLA if they are allergic to fenfluramine or any other ingredients in FINTEPLA, or if they have taken medicines called monoamine oxidase inhibitors (MAOIs) in the last 14 days. This may cause a serious or life-threatening problem called serotonin syndrome. If there is uncertainty about whether they have taken one of these medicines, talk to your healthcare provider.

†Talk to your loved one's healthcare provider about all of their medical conditions and medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

IMPORTANT SAFETY INFORMATION (cont.)

How can I watch for early symptoms of suicidal thoughts and actions?

Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled.

Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

- 5. Do not stop taking FINTEPLA without first talking to your healthcare provider.** Stopping a seizure medicine such as FINTEPLA can suddenly cause you to have seizures more often or seizures that do not stop (status epilepticus).

Please see full Important Safety Information on pages 13-15 and full Prescribing Information, including Medication Guide.

FINTEPLA REMS was designed with your loved one's safety in mind

Here's some safety information to know about FINTEPLA as you and your loved one's healthcare team decide if starting treatment is right for them:



FINTEPLA is available only through FINTEPLA REMS due to the risk of potential problems with valves in the heart (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension).



Your loved one's doctor **will proactively order heart tests (echocardiograms)** before, during, and one time after the last dose to make sure there are no heart issues.



Help is available through ONWARD® with identifying where to receive these required echocardiograms, either at a doctor's office or at home.



Since the approval of FINTEPLA in June 2020 for seizures associated with Dravet syndrome and March 2022 for seizures associated with LGS, **more than 10,000 patients worldwide have been prescribed FINTEPLA.**

The most common side effects of FINTEPLA in LGS include:

- Diarrhea
- Tiredness
- Vomiting
- Sleepiness
- Decreased appetite

Approximately half of patients with LGS resumed expected weight gains during the open-label extension study. In the open-label extension, results were consistent: Most TEAEs reported were mild to moderate in severity.

6% of the patients at the 0.7 mg/kg/day dose discontinued treatment due to side effects.

These are not all the possible side effects of FINTEPLA. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

**Call your healthcare provider for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088.**

REMS, Risk Evaluation and Mitigation Strategy; TEAE, treatment-emergent adverse event.

FINTEPLA support along the way

ONWARD[®] provides dedicated one-on-one support to help move you forward.



Fintepla[®]
(fenfluramine)
2.2 mg/mL oral solution

FINTEPLA Clinical Nurse Educators (CNEs)

are nurses and experts in Lennox-Gastaut syndrome who answer questions and provide treatment education for families starting FINTEPLA.*



Get in touch with a Clinical Nurse Educator by calling
1-833-GO-DS-LGS (1-833-463-7547).

Call any time from 7:30 AM to 4:30 PM Central Time, Monday through Friday, and ask to talk with a Clinical Nurse Educator.

*Clinical Nurse Educators cannot provide medical advice or make treatment recommendations. They can only provide information about FINTEPLA. Decisions regarding your loved one's health and the treatment of their condition should be made with their healthcare provider.

Visit [FINTEPLA.com](https://www.fintepla.com) for more info about support to help get you started on FINTEPLA.

INDICATION

- FINTEPLA is a prescription medicine used to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older.
- It is not known if FINTEPLA is safe and effective in children less than 2 years of age.

IMPORTANT SAFETY INFORMATION

FINTEPLA can cause serious side effects, including:

- 1. Problems with the valves in the heart (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension)** have been associated with FINTEPLA. Your healthcare provider will do a test called an echocardiogram to check your heart and to evaluate for high blood pressure in the arteries of the lungs before you start taking FINTEPLA, again every 6 months during treatment, and one time 3 to 6 months after you take your last dose of FINTEPLA.

Call your healthcare provider right away if you develop any of these signs and symptoms of heart or lung problems during treatment with FINTEPLA:

- shortness of breath
- chest pain
- tiredness or weakness, especially with increased activity
- sensations of a rapid, fluttering heartbeat (palpitations)
- lightheadedness or fainting
- irregular pulse
- swollen ankles or feet
- bluish color of your lips and skin (cyanosis)

Because of the risk of heart valve problems (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension), FINTEPLA is only available through a restricted program called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS). Before you or your child receives FINTEPLA, your healthcare provider or pharmacist will make sure you understand how to take FINTEPLA safely. If you have any questions about FINTEPLA, ask your healthcare provider, visit www.FinteplaREMS.com, or call 1-877-964-3649.

- 2. Decreased appetite and decreased weight.** Decreased appetite and decreased weight are serious and common side effects of FINTEPLA.
 - Your weight should be checked regularly during your treatment with FINTEPLA.
 - Your healthcare provider may need to make changes to your FINTEPLA dose if your weight decreases. In some cases, FINTEPLA may need to be stopped.
- 3. Sleepiness, sedation, and lack of energy (lethargy).** These are serious and common side effects of FINTEPLA. Taking FINTEPLA with central nervous system (CNS) depressants, including alcohol, may increase sleepiness. **Do not** drive, operate heavy machinery, or do other dangerous activities until you know how FINTEPLA affects you.
- 4. Like all other antiepileptic drugs, FINTEPLA may cause suicidal thoughts or actions** in a very small number of people (about 1 in 500). **Call your healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:**

Please see full Important Safety Information on pages 13-15 and full Prescribing Information, including Medication Guide.

IMPORTANT SAFETY INFORMATION (cont.)

Fintepla®
(fenfluramine)
2.2 mg/mL oral solution

thoughts about suicide or dying; trouble sleeping (insomnia); attempts to commit suicide; new or worse irritability; new or worse depression; acting aggressive, being angry or violent; new or worse anxiety; acting on dangerous impulses; feeling agitated or restless; an extreme increase in activity and talking (mania); panic attacks; other unusual changes in behavior or mood.

How can I watch for early symptoms of suicidal thoughts and actions?

Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled.

Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

- 5. Do not stop taking FINTEPLA without first talking to your healthcare provider.** Stopping a seizure medicine such as FINTEPLA can suddenly cause you to have seizures more often or seizures that do not stop (status epilepticus).

Do not take FINTEPLA if you:

- are allergic to fenfluramine or any of the ingredients in FINTEPLA. See the Medication Guide for a complete list of ingredients in FINTEPLA.
- are taking or have stopped taking medicines called monoamine oxidase inhibitors (MAOIs) in the last 14 days. This may cause a serious or life-threatening problem called **serotonin syndrome**. If you are not sure whether or not you are taking one of these medicines, contact your healthcare provider.

Before taking FINTEPLA, tell your healthcare provider about all your medical conditions, including heart problems; weight loss; depression, mood problems, or suicidal thoughts or behavior; kidney problems; liver problems; are pregnant or plan to become pregnant; are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of FINTEPLA?

FINTEPLA may cause serious side effects, including:

- See “FINTEPLA can cause serious side effects” above
- **Serotonin syndrome.** Serotonin syndrome is a life-threatening problem that can happen in people taking FINTEPLA, especially if FINTEPLA is taken with certain other medicines, including anti-depressant medicines called SSRIs, SNRIs, TCAs, and MAOIs; tryptophan; lithium; antipsychotics; St. John’s Wort; dextromethorphan; tramadol.

Call your healthcare provider right away if you have any of the following symptoms of serotonin syndrome: mental status changes such as seeing things that are not there (hallucinations), agitation, or coma; changes in blood pressure; tight muscles; fast heartbeat; nausea, vomiting, or diarrhea; high body temperature; trouble walking.

- **High blood pressure (hypertension).** Hypertension is a serious and common side effect. FINTEPLA can cause your blood pressure to increase even if you have never had high blood pressure before.

- **Increased pressure in your eyes (glaucoma).** Symptoms of glaucoma may include red eyes, seeing halos or bright colors around lights, nausea or vomiting, decreased vision, eye pain or discomfort, blurred vision. If you have any of these symptoms, call your healthcare provider right away.

The most common side effects of FINTEPLA when used to treat patients with Dravet syndrome (DS) include decreased appetite; diarrhea; low energy; respiratory infection; decreased weight; fever; constipation; abnormal echocardiogram; sleepiness; problems with movement, balance, and walking; increased drooling; increased blood pressure; vomiting; falls; seizures that do not stop; weakness.

The most common side effects of FINTEPLA when used to treat patients with Lennox-Gastaut syndrome (LGS) include diarrhea; tiredness; vomiting; sleepiness; decreased appetite.

These are not all the possible side effects of FINTEPLA. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. Keep FINTEPLA and all medicines out of the reach of children.

Please see full **Prescribing Information**, including **Medication Guide**, for additional **Important Safety Information on FINTEPLA.**

For seizures associated with **Lennox-Gastaut syndrome (LGS)** in patients ages 2 and older

Fintepla[®]
(fenfluramine)
2.2 mg/mL oral solution

**EXPERIENCE FINTEPLA
FAMILY MOMENTS**

Lucas, living
life with LGS

**WORTH
FIGHTING
FOR**

Visit [FINTEPLA.com](https://www.fintepla.com) to see more stories of families like yours.

INDICATION

- FINTEPLA is a prescription medicine used to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older.
- It is not known if FINTEPLA is safe and effective in children less than 2 years of age.

SELECT IMPORTANT SAFETY INFORMATION

FINTEPLA can cause serious side effects, including:

Problems with the valves in the heart (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension) have been associated with FINTEPLA. Your healthcare provider will do a test called an echocardiogram to check your heart and to evaluate for high blood pressure in the arteries of the lungs before you start taking FINTEPLA, again every 6 months during treatment, and one time 3 to 6 months after you take your last dose of FINTEPLA.

Please see full Important Safety Information on pages 13-15 and full Prescribing Information, including Medication Guide.

 Inspired by **patients.**
Driven by **science.**

FINTEPLA[®] and ONWARD[®] are registered trademarks of the UCB Group of Companies.
©2025 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-FA-2500291